FDA medtech regulators put the stamp of approval on Global Kinetic Corp.’s Personal KinetiGraph, a wearable device designed to help physicians diagnose symptoms of Parkinson’s disease and other movement-based disorders.
The Personal KinetiGraph is the 1st device of its kind, capturing movement outside of the clinic and creating automated reports that neurologists and other caregivers can use to identify signs of neurological disorders. Most Parkinson’s diagnoses today are done with in-clinic evaluations, patient’s personal reports of symptoms and reactions to medication, Global Kinetic said.
"Monitoring changes in a patient’s movement symptoms is a critical element in the treatment of Parkinson’s and many other movement disorders, but it can be difficult for both patients and healthcare providers to identify and assess changes in movement symptoms effectively," Global Kinetics CEO and managing director Andrew Maxwell said in prepared remarks. "The Personal KinetiGraph provides clinicians with a clear and accurate assessment of the patient experience outside of office visits and examinations."
The KinetiGraph is about the size and shape of a wristwatch, intended for 10 days of continuous monitoring. The device also providers the wearer with medication reminders.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.